AIPPI 2018: Dawn of big data for pharma industry, says J&J counsel

Big data presents an array of opportunities for the pharmaceutical industry, but companies must be careful who they partner with, said Myra McCormack, associate patent counsel at Johnson & Johnson, yesterday.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

Biotech

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

Biotech

Insilico lands potential $2.5bn AI biotech partnership

22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.

More features

Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

UPC revives patent, but timing sinks Guardant’s appeal

China’s medtech shake-up forces rethink on pricing, IP and innovation

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

AIPPI 2018: Dawn of big data for pharma industry, says J&J counsel

More on this story

Editor's picks

Editor's picks

More features